A role for the C2 domain of factor VIII in binding to von Willebrand factor

scientific article published on 01 April 1994

A role for the C2 domain of factor VIII in binding to von Willebrand factor is …
instance of (P31):
scholarly articleQ13442814

External links are
P698PubMed publication ID7512568

P2093author name stringSaenko EL
Shima M
Scandella D
Rajalakshmi KJ
P433issue15
P407language of work or nameEnglishQ1860
P304page(s)11601-11605
P577publication date1994-04-01
P1433published inJournal of Biological ChemistryQ867727
P1476titleA role for the C2 domain of factor VIII in binding to von Willebrand factor
P478volume269

Reverse relations

cites work (P2860)
Q52590007An intronic mutation c.6430-3C>G in the F8 gene causes splicing efficiency and premature termination in hemophilia A.
Q36447889Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation
Q37382199B-cell and T-cell epitopes in anti-factor VIII immune responses
Q41721581Binding of Factor VIII to Lipid Nanodiscs Increases its Clotting Function in a Mouse Model of Hemophilia A.
Q42036652Binding of blood coagulation factor VIII and its light chain to phosphatidylserine/phosphatidylcholine bilayers as measured by ellipsometry.
Q35602099Blood coagulation factor VIII: An overview
Q37378510Characteristics, mechanisms of action, and epitope mapping of anti-factor VIII antibodies.
Q36742268Characterization and solution structure of the factor VIII C2 domain in a ternary complex with classical and non-classical inhibitor antibodies
Q36621449Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa
Q42213583FVIII-VWF dos-à-dos
Q34055694Factor VIII lacking the C2 domain retains cofactor activity in vitro
Q36317966Highly conserved antigenic structure of the factor VIII C2 domain in some mammals.
Q34744656Immunogenicity and pharmacokinetic studies of recombinant factor VIII containing lipid cochleates
Q92212325Interaction Between the a3 Region of Factor VIII and the TIL'E' Domains of the von Willebrand Factor
Q41167453Intracellular retention of a factor VIII protein with an Arg2307-->Gln mutation as a cause of haemophilia A.
Q35498838Intravenous administration of Factor VIII-O-Phospho-L-Serine (OPLS) complex reduces immunogenicity and preserves pharmacokinetics of the therapeutic protein
Q36970547Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-L-serine complex
Q37382208Management of haemophilia A-inhibitor patients: clinical and regulatory perspectives
Q41850873Mapping the interaction between factor VIII and von Willebrand factor by electron microscopy and mass spectrometry
Q92619754Molecular Mechanisms of Inhibitor Development in Hemophilia
Q33962546Non-classical anti-factor VIII C2 domain antibodies are pathogenic in a murine in vivo bleeding model.
Q36835121Nonclassical anti-C2 domain antibodies are present in patients with factor VIII inhibitors
Q33954639Phosphatidylinositol containing lipidic particles reduces immunogenicity and catabolism of factor VIII in hemophilia a mice
Q34688731Phosphatidylserine reduces immune response against human recombinant Factor VIII in Hemophilia A mice by regulation of dendritic cell function
Q85025577Phospholipid binding improves plasma survival of factor VIII
Q80273707Relationship between the binding sites for von Willebrand factor, phospholipid, and human factor VIII C2 inhibitor alloantibodies within the factor VIII C2 domain
Q35007278Six amino acid residues in a 1200 Å2 interface mediate binding of factor VIII to an IgG4κ inhibitory antibody
Q27680123Structure of the factor VIII C2 domain in a ternary complex with 2 inhibitor antibodies reveals classical and nonclassical epitopes
Q35578480The 1.7 Å X-ray crystal structure of the porcine factor VIII C2 domain and binding analysis to anti-human C2 domain antibodies and phospholipid surfaces
Q35832756The important role of von Willebrand factor in platelet-derived FVIII gene therapy for murine hemophilia A in the presence of inhibitory antibodies.
Q45866649The structural basis for the functional comparability of factor VIII and the long-acting variant recombinant factor VIII Fc fusion protein
Q27648918The tertiary structure and domain organization of coagulation factor VIII

Search more.